Print ISSN:-2581-5555
Online ISSN:-2456-9542
CODEN : IIJCDU
Review Article
Author Details :
Volume : 9, Issue : 4, Year : 2024
Article Page : 221-226
https://doi.org/10.18231/j.ijcaap.2024.033
Abstract
Targeted drug delivery to the colon is highly desirable for the local treatment of various bowel diseases, including ulcerative colitis, Crohn’s disease, amebiasis, and colonic cancer, as well as for the systemic delivery of protein and peptide drugs. The colon-specific drug delivery system (CDDS) must protect the drug during transit through the stomach and small intestine, ensuring that release and absorption occur only in the colon. The colon is an ideal site for drug absorption due to its lower enzymatic activity compared to the small intestine, which helps protect peptide drugs from degradation, and its long residence time, which enhances systemic bioavailability.While the oral route is the most convenient for CDDS, rectal administration is also used, though it can be uncomfortable and less effective for targeting the proximal colon. Intrarectal drug preparations, such as solutions, foams, and suppositories, are used for both systemic dosing and local treatment of the large intestine. The efficacy of these drugs often depends on their formulation, spreading capacity, and retention time.The colon’s high water absorption capacity and viscous contents can limit drug availability to the absorptive membrane. However, the presence of a diverse bacterial flora in the colon can be leveraged for drug metabolism and targeted delivery of peptide-based macromolecules, such as insulin. Understanding the anatomy and physiology of the gastrointestinal tract (GIT), including variations in pH, is crucial for designing effective CDDS. This knowledge helps optimize drug release and absorption, ultimately improving therapeutic outcomes for patients.
Keywords: Colonspecific drug delivery, Ulcerative colitis, Peptide drugs, Gastrointestinal tract (GIT), Enzymatic degradation
How to cite : Reddy G J, Kokkula P K, Kannadasan M, Colonic drug delivery systems: Exploring the potential of biodegradable polymers for systemic effects. IP Int J Compr Adv Pharmacol 2024;9(4):221-226
This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.